Skip to main content

RX Updates

The Future of PsA

RheumNow
As we conclude our PsA campaign, Dr. Ogdie shares information about Preventing PsA and Dr. Ritchlin discusses Future Discovery and Targets.

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Sponsored by Novartis
Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs
Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Sponsored by Novartis Medical Affairs
The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

The Science of Upadacitinib in Psoriatic Arthritis

Sponsored by AbbVie Medical Affairs

Comorbidities in axSpA: A Focus on Cardiovascular Features

Sponsored by Novartis Medical Affairs
Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.

Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA): Current Challenges and Future Outlook

Sponsored by Novartis Medical Affairs
There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.

Women Leaders in Rheumatology: Leadership in a Virtual World

Sponsored by Bristol Myers Squibb and the Bristol Myers Squibb Network of Women (B-NOW)
A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic.

Expert-Selected EULAR 2021 Abstracts

Sponsored by Novartis Medical Affairs
Didn’t have time to join EULAR 2021? Listen to a panel of experts as they present their views on the key abstracts in SpA and Still’s disease.

Expert Perspectives on Lupus Nephritis

Sponsored by GSK US Medical Affairs
In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.

Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration

Sponsored by Novartis Medical Affairs
Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.
×